Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Total transaction value of the divestment is Rs. 3,660 million
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated
